|Articles|April 1, 1998

Clinical and Economic Considerations of Helicobacter pylori Eradication and Screening
Volume 4
Issue 5 Suppl

Current Issues in H pylori Eradication

Author(s)M. Brian Fennerty, MD

Download PDF: Current Issues in H pylori Eradication

Articles in this issue

about 28 years ago

Article

Participating Faculty

about 28 years ago

Article

The Impact of H Pylori Eradication on Your Pharmacy Budget

about 28 years ago

Article

Overview of H pylori in Peptic Ulcer Disease

about 28 years ago

Article

Clinical Issues and Cost Effectiveness of Treating H pylori

about 28 years ago

Article

Evaluation of Outcomes Achieved Through Peptic Ulcer Disease State Management

about 28 years ago

Article

Is Curing Peptic Ulcer Disease an Oxymoron? A Focus on Helicobacter pylori

about 28 years ago

Article

CPE Quiz

about 28 years ago

Article

Selected Abstracts

about 28 years ago

Article

Bibliography

about 28 years ago

Article

Efficacy and Economic Concerns Regarding H pylori Treatment in the Managed Care Setting

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Current Issues in H pylori Eradication

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

ATTR-CM Incidence, Prevalence Rose Sharply in the US

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Current Issues in H pylori Eradication

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

ATTR-CM Incidence, Prevalence Rose Sharply in the US

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care